Melanoma Indication

PD-1/PD-L1 Combination Strategies

​Malignant melanoma is a complex, multifactorial disease, which is responsible for up to 75% of skin cancer related deaths globally.

With the US FDA approval of ipilimumab (CTLA-4 targeting agent) in 2011 for the treatment of advanced melanoma patients, clinical research intensity has gradually shifted towards Immune Checkpoint Inhibitors (ICIs) & their Combination agents. 

After the approval of nivolumab and pembrolizumab (both are PD-1 targeting agents), it is imperative to understand how PD-1/PD-L1 clinical landscape is evolving in melanoma.
​

Read More